250+ investors that invest in your industry and stage
Get 250+ investors tailored to your startup
  • Invest in your industry and stage
  • Emails & contact info included
  • Excel and CSV export
  • Automatically
Trusted by 3,000+ startups

Top 50 Life Science Startup Investors in May 2025

A list of 50 angel investors and VC (Venture Capital) funds that invest in Life science startups. We rank investors based on the number of investments they made in Life science companies. This investor list updates every month.

Top 50 Life Science Startup Investors in May 2025

Investor Life Science investments
SOSV 51
ARCH Venture Partners 28
Sofinnova Partners 25
Alexandria Venture Investments 23
Northpond Ventures 20
Parkwalk Advisors 18
RA Capital Management 17
Novartis Venture Fund 17
Google Ventures 16
OrbiMed 16
Oxford Science Enterprises 15
Fifty Years 15
UK Innovation & Science Seed Fund 15
8VC 14
Versant Ventures 14
Atlas Venture 14
Bpifrance 13
Third Rock Ventures 13
DCVC 13
SR One 13
Civilization Ventures 12
Prox Ventures 12
Alix Ventures 12
Jonathan Milner 11
Hatteras Venture Partners 11
Andreessen Horowitz 11
Horizons Ventures 11
M Ventures 11
Kurma Partners 11
MPM Capital 11
Lux Capital 11
KdT Ventures 11
Roche Venture Fund 10
Takeda Ventures 10
Casdin Capital 10
Novo Holdings 10
Sahsen Ventures 10
Omega Funds 10
Dementia Discovery Fund 10
JDRF T1D Fund 9
5AM Ventures 9
Seventure Partners 9
Khosla Ventures 9
Artis Ventures 9
Rev1 Ventures 9
Cormorant Asset Management 9
F-Prime Capital 9
High-Tech Gruenderfonds 9
Oxford Science Enterprises 9
New Enterprise Associates 9
Find investors that fund startups like yours. Automatically.
Our algorithm will find investors that invest in your industry, stage, and geography.
Investor list
SOSV VC Fund · Princeton, New Jersey, United States · 70 investments in the past 12 months
SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.
Show more
Investment focus
  • Biotechnology, Health Care, Software
  • Seed, Convertible Note, Pre-Seed
  • United States, India, United Kingdom
Portfolio highlights
  • MixRift — MIXRIFT - game developers specialized in Mixed Reality
  • unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
  • Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.
ARCH Venture Partners VC Fund · Chicago, Illinois, United States · 19 investments in the past 12 months
ARCH Venture Partners provides seed / early stage venture capital for technology firms in information technology, life sciences, and physical sciences
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Series C
  • United States, China, United Kingdom
Portfolio highlights
  • Rhygaze — RhyGaze is at the forefront of developing a novel first-in-class gene therapy aimed at improving vision in patients suffering from retinal diseases.
  • Kardigan — Kardigan is building the heart health company of the future focused on developing medicines to make cardiovascular disease curable, preventable, and no longer the leading cause of death.
  • Be Biopharma — Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.
Sofinnova Partners VC Fund · Paris, Ile-de-France, France · 20 investments in the past 12 months
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Series A, Series B, Series C
  • France, United States, United Kingdom
Portfolio highlights
  • Latent Labs — Latent Labs is making biology programmable to transform health and sustainability for the benefit of all.We are a frontier AI lab building foundational models that capture the fundamentals of biology. We empower partners with breakthrough generative AI to gain unprecedented control over molecular biology, creating new antibodies, optimizingexisting enzymes, and advancing genetic engineering.Contact us to work with us today.
  • Signadori Bio — Signadori Bio is the next-generation cellular immunotherapy for cancer cure.This has culminated in the creation of a groundbreaking biotech venture in the cell and gene space that is set to advance innovative approaches in oncology.
  • Forth Therapeutics — Forth Therapeutics is a biotechnology company dedicated to advancing precision treatments for fibrosis.
Alexandria Venture Investments VC Fund · Pasadena, California, United States · 29 investments in the past 12 months
Alexandria Venture Investments is a venture capital firm that develops work in real estate technology, and healthcare sectors. The company's strategic venture capital platform is Alexandria Venture Investments. Since its inception in 1996, the company has invested in disruptive life science, agrifood tech, and technology companies that aredeveloping transformative new modalities and platforms to meaningfully improve human health.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Seed
  • United States, Canada, France
Portfolio highlights
  • Remedy Plan Therapeutics — Remedy Plan is a biotechnology company developing the first drugs that halt tumor growth and disrupt the cancer stem cells that cause metastasis.
  • Hoofprint Biome — Hoofprint Biome, developing probiotics for to increase feed digestibility and decreasing methane in cattle
  • HAYA Therapeutics — Pioneering next-generation therapies for fibrotic diseases. Learn more about our approach here.
Northpond Ventures VC Fund · Bethesda, Maryland, United States · 3 investments in the past 12 months
Northpond Ventures is a science-driven venture capital firm headquartered in Bethesda, Maryland. Our mission is to build a better tomorrow. Our investments are focused on life sciences, technology, and affiliated industries.
Show more
Investment focus
  • Biotechnology, Health Care, Life Science
  • Series A, Series B, Series C
  • United States, United Kingdom, Canada
Portfolio highlights
  • Vizgen — The next generation of genomics, expanding the impact of spatial context and demonstrating the potential of in situ single-cell spatial genomics.
  • VieCure — The VieCure platform is an Clinical Decision Support solution in Oncology that combines the power of artificial intelligence, codified clinical rules and pathways, precision oncology, telehealth, smartphone technology, and the EMR to transform cancer care.
  • Inflammatix — Inflammatix develops rapid point of care diagnostic tests by reading the immune system, and resolves major clinical health challenges.
Parkwalk Advisors VC Fund · London, England, United Kingdom · 11 investments in the past 12 months
Parkwalk is a London-based fund management firm. Parkwalk invests in UK technology companies that have IP backing and freedom to operate, generally spun out of UK universities. Their funds seek to generate capital gains for their investors, enhanced by the attractive tax relief provided by EIS. Parkwalk entered this investment sector in 2009,anticipating a wave of tax-efficient incentives launched by the UK Government to stimulate innovative emerging technology companies and thereby help drive economic growth.Parkwalk utilises academic, technology transfer, venture capital and personal networks developed over many years to gain access to the highest calibre deal-flow. In 2017 Parkwalk joined forces with IP Group plc, a leading intellectual property commercialisation company that is listed on the Main Market of the London Stock Exchange under the ticker symbol IPO. As at March 2019 the combined group has net assets of £1.2bn.
Show more
Investment focus
  • Biotechnology, Health Care, Software
  • Seed, Series A, Series B
  • United Kingdom, United States, Philippines
Portfolio highlights
  • Diffblue — Diffblue Cover uses next generation autonomous AI to automate unit testing so that Java development teams can build better applications faster
  • illumion — Illumion develops high-throughput optical tools to accelerate battery material development
  • Brainomix — Since launching as a spin-out from the University of Oxford in 2010, Brainomix has developed award-winning, AI-powered imaging biomarkers, assisting physicians across the world to make better life-saving decisions. Brainomix seminal product, e-Stroke is a collection of tools that use state-of-the-art AI algorithms to support doctors by providingreal-time interpretation of brain scans to help guide treatment and transfer decisions for stroke patients, allowing more patients to get the right treatment, in the right place, at the right time.
RA Capital Management VC Fund · Boston, Massachusetts, United States · 43 investments in the past 12 months
RA Capital Management is an investment advisor based in Boston specializing in the life-sciences and drug development sectors. The company's team has been investing since 2002 and is comprised of professionals with training in biology, chemistry, and medicine and also has industry and business development experience at the executive and boardlevels. The company invests in companies with promising technologies and products.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series B, Series C, Post-IPO Equity
  • United States, United Kingdom, Canada
Portfolio highlights
  • Stylus Medicine — Stylus Medicine, Inc. is a biotechnology company dedicated to developing transformative in vivo genetic medicines.
  • Jade Biosciences — Jade Biosciences is developing transformative therapies to redefine the standard of care for inflammation and immunology indications.
  • Imbria Pharmaceuticals — Imbria is a clinical-stage, cardio-metabolic company developing innovative cellular energy enhancing therapies for the treatment of cardiovascular disorders
Novartis Venture Fund VC Fund · Basel, Basel-Stadt, Switzerland · 11 investments in the past 12 months
Learn about the approach the Novartis Venture Fund takes to investing in innovative life science companies developing biotechnology and biopharmaceutical therapeutics that address unmet patient needs.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Series C
  • United States, Switzerland, United Kingdom
Portfolio highlights
  • Rhygaze — RhyGaze is at the forefront of developing a novel first-in-class gene therapy aimed at improving vision in patients suffering from retinal diseases.
  • Granite Bio — Targeting fundamentals of Inflammation, Autoimmunity and Fibrosis. Granite Bio develops first-in-class therapeutic antibodies depleting pathogenic cells with the potential to transform inflammatory and fibrotic diseases.
  • Atalanta Therapeutics — Atalanta was created to address the urgent global need for interventions to treat neurodegenerative diseases.
Google Ventures VC Fund · Mountain View, California, United States · 58 investments in the past 12 months
GV supports innovative founders moving the world forward.
Show more
Investment focus
  • Software, Health Care, Biotechnology
  • Series A, Series B, Seed
  • United States, United Kingdom, Switzerland
Portfolio highlights
  • Veza — Veza is the identity security company that enables organizations to understand, manage and control who can and should take what action on what data.
  • Blacksmith — Blacksmith is a company that helps businesses to conduct their continuous integration (CI) up to twice as quickly and at half the expense. Blacksmith accomplish this by running CI on powerful gaming CPUs.
  • Glass Imaging — Traditional cameras rely on an imaging lens which typically consists of several lens elements and a light sensitive sensor. Cameras have been built like this since 1816. Glass has been historically used to make high quality optical elements. We are replacing these elements with deep neural networks that give extreme flexibility when designing ourcameras. It allows us to squeeze a huge sensor into an ultra thin module that fits perfectly into a mobile device without the need for protruding bumps. Our cameras bring SLR image quality into your pocket.
OrbiMed VC Fund · New York, New York, United States · 32 investments in the past 12 months
Leading Global Healthcare Platform with Deep Proprietary Resources and Global Industry Coverage.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Series B, Series A, Series C
  • United States, China, Israel
Portfolio highlights
  • RayThera — RayThera specializes in developing breakthrough small molecule therapies for critical unmet needs in immunology. Backed by decades of drug discovery expertise, we accelerate the development process while maintaining rigorous standards.
  • Stairway Medical — Stairway Medical is a developer of implantable brain-computer interface technology.
  • Edgewise Therapeutics — See how we bring our unique expertise and singular focus on muscle science to develop novel therapeutics for serious skeletal and cardiac muscle diseases.
Oxford Science Enterprises VC Fund · Oxford, Oxfordshire, United Kingdom · 9 investments in the past 12 months
Oxford Science Enterprises is the university-partnered venture firm. We work with the University of Oxford to build companies that create fundamental technologies: science-based businesses capable of tackling the planet’s toughest problems. We invest in life science, AI and software, healthcare, and deep tech to create companies taking onchallenges like nuclear fusion, quantum computing and developing treatments and cures for infectious diseases. Founded in 2015, we’ve raised over £600M to create a world-class technology ecosystem, and combine our deep experience with a network of investors, entrepreneurs and sector-experts to find co-investment, build businesses, and hire senior management talent.
Show more
Investment focus
  • Health Care, Biotechnology, Software
  • Seed, Series A, Series B
  • United Kingdom, United States, Finland
Portfolio highlights
  • FluoRok — By employing our patented technology, we can produce fluorochemicals without the production of toxic and highly dangerous hydrofluoric acid
  • Neu Health — Neu Health enables clinicians, care givers and patients to tackle this growing challenge with cutting-edge digital technologies designed to make the latest care accessible for all, improving outcomes today and accelerating future breakthroughs.
  • Salience Labs — Salience Labs is building a hybrid photonic-electronic chip for AI. We have designed a massively parallel, ultra-high-throughput Photonic Tensor Processing Unit. Photonics allows data to be modulated at up to 100 GHZ, and allows for high levels of parallelization using multiplexing. We integrate this photonic unit into a SoC architecture designedto exploit its high throughput for AI inference. Salience Labs technology is based on decades of research collaboration between Oxford University and the University of Münster, Germany.
Fifty Years VC Fund · San Francisco, California, United States · 6 investments in the past 12 months
WE BACK HEROES using technology to solve the world's biggest problems
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Seed, Series A, Series B
  • United States, Germany, Canada
Portfolio highlights
  • Deepcell — Deepcell uses AI to isolate and capture cells based on morphological features for multiple research and translational applications.
  • Gridware — Using remote telemetry and edge AI, Gridware wildfire prevention technology powers a grid that is smarter and more reliable than ever before.
  • Aalo Atomics — Creating abundant and dependable clean energy to power humanity for generations.
UK Innovation & Science Seed Fund VC Fund · Harwell, Oxfordshire, United Kingdom · 11 investments in the past 12 months
UKI2S, formally the Rainbow Seed Fund, is an investment fund backed by the government, providing seed funding to science & technology start-ups and SMEs
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Seed, Funding Round, Series A
  • United Kingdom, United States
Portfolio highlights
  • Ikarovec — Ikarovec is developing novel gene therapies to treat major ophthalmic indications.
  • Antiverse — Designing biologics for 100 challenging targets
  • iFast Diagnostics — iFAST is addressing the Antimicrobial Susceptibility Testing market, reducing the spread of antimicrobial resistance.
8VC VC Fund · San Francisco, California, United States · 41 investments in the past 12 months
8VC is a technology and life sciences investment firm that partners with founders to develop transformational technologies. The firm focuses on creating long-term economic and societal value through its investments across various sectors, including healthcare and logistics.
Show more
Investment focus
  • Software, Health Care, Artificial Intelligence
  • Seed, Series A, Series B
  • United States, Canada, United Kingdom
Portfolio highlights
  • Gallatin — Gallatin is building a logistics platform based on the needs and constraints of today's defense industry. Gallatin's platform creates actionable insights across the tactical, operational, and strategic levels providing integrated capabilities for first, middle, and last mile solutions where they're needed most.
  • Apex — Apex manufactures ESPA-class satellites, ranging from 40 to 400kg. Our first spacecraft bus platform, Aries, is built for LEO missions for earth observation, communications, and more. Configure the Aries bus to meet your specific mission profile.
  • Chaos — The future of defense and critical industry technology. Creating that which has never been.
Versant Ventures VC Fund · Menlo Park, California, United States · 9 investments in the past 12 months
Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Series A, Series B, Series C
  • United States, Switzerland, Canada
Portfolio highlights
  • Granite Bio — Targeting fundamentals of Inflammation, Autoimmunity and Fibrosis. Granite Bio develops first-in-class therapeutic antibodies depleting pathogenic cells with the potential to transform inflammatory and fibrotic diseases.
  • Helicore Biopharma — Helicore Biopharma is at the forefront of developing cutting-edge treatments for obesity and related disorders.
  • Light Horse Therapeutics — Light Horse Therapeutics is the gene editing applied to small-molecule drug discovery, pioneering approaches to target the root causes of disabling and life-threatening diseases. Its advanced platform identifies cryptic chemically accessible functional domains within targets that are critical in disease biology. Our initial focus addresseshigh-value, historically challenging oncology targets with the opportunity to apply the technology to other therapeutic areas in the future.
Atlas Venture VC Fund · Cambridge, Massachusetts, United States · 11 investments in the past 12 months
Atlas Venture is an early-stage venture capital firm that creates and invests in biotech startup companies led by promising entrepreneurs focusing on life sciences innovation. Its seed-led venture creation strategy rigorously selects and focuses investment on compelling opportunities to build scalable businesses and realize value.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Series C
  • United States, United Kingdom, Canada
Portfolio highlights
  • Judo Bio — Judo Bio is pioneering oligonucleotide medicines delivered to the kidney, opening the way for new treatments for systemic and renal diseases.
  • Be Biopharma — Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.
  • Trace Neuroscience — Trace Neuroscience is a biopharmaceutical company that aims to extend the promise of genetic medicine to patients with neurodegenerative illnesses.
Bpifrance VC Fund · Maisons-alfort, Ile-de-France, France · 93 investments in the past 12 months
Bpifrance provides financial solutions for companies that are booting up the listing on the stock exchange and credit equity. It includes OSEO, CDC Entreprises, FSI, and FSI Regions to offer in your area of financial solutions at every stage of the life of your business.
Show more
Investment focus
  • Software, Information Technology, Health Care
  • Seed, Funding Round, Series A
  • France, United States, Switzerland
Portfolio highlights
  • Lprint — Lprint revolutionise the way PCBs are designed and manufactured, empowering hardware engineers and product development teams. Lprint is a 3D electronic printing system for PCBs, designed to manufacture complex, free-form printed circuit boards (PCBs) in a single step, simplifying the prototyping, testing, and manufacturing process of electronics.
  • Veesion — Veesion: AI-driven smart video surveillance. Detect theft in real time. Protect your business now.
  • PyxiScience — PyxiScience operates as an adaptive Math Learning Platform designed by educators and powered by AI.
Third Rock Ventures VC Fund · Boston, Massachusetts, United States · 7 investments in the past 12 months
Third Rock Ventures invests in transformational life science companies that show high growth potential and are well-positioned to make a difference in the marketplace. Third Rock Ventures believes in the companies we start and makes significant initial investments, which are frequently supplemented by strategic collaborations, to help our firmsprogress in life-changing medicines, technologies, and diagnostics.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Series C
  • United States
Portfolio highlights
  • Trace Neuroscience — Trace Neuroscience is a biopharmaceutical company that aims to extend the promise of genetic medicine to patients with neurodegenerative illnesses.
  • Candid Therapeutics — Candid Therapeutics is a biotechnology company that focuses on the treatment of a range of immunological conditions.
  • Seaport Therapeutics — Seaport Therapeutics operates as a clinical stage biopharmaceutical company.
DCVC VC Fund · San Francisco, California, United States · 19 investments in the past 12 months
We are deep tech venture capital.
Show more
Investment focus
  • Software, Artificial Intelligence, Health Care
  • Seed, Series A, Series B
  • United States, Canada, United Kingdom
Portfolio highlights
  • Lumafield — Lumafield's easy-to-use CT scanner and cloud-based software give engineers the ability to see their work clearly, inside and out.
  • Fervo Energy — Fervo Energy delivers 24/7 carbon-free energy through development of next-generation geothermal projects.
  • Alta Resource Technologies — Alta Resource Technologies is on a mission to reinvent mining by harnessing advanced biochemistry to cost-effectively source the critical raw materials needed to power next-generation technology and bolster economic security. Our groundbreaking technology platform leverages customizable proteins to separate high-purity rare earth elements and otheressential minerals with unprecedented selectivity while dramatically reducing the environmental impact of mining.
SR One VC Fund · Cambridge, Massachusetts, United States · 10 investments in the past 12 months
SR One Capital Management is a leading trans-Atlantic biotech venture capital firm that partners with top entrepreneurs, scientists and investment partners to seek to build elite biotechnology companies. Our mission is to translate ground-breaking technologies into next generation medicines to benef
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Series C
  • United States, United Kingdom, Canada
Portfolio highlights
  • Fore Biotherapeutics — We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics.
  • Windward Bio — Windward Bio is a clinical-stage drug development company focused on improving outcomes for individuals with advanced immunological diseases, particularly severe respiratory conditions. The company is advancing a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 development while creating innovative bispecific programsfor various immunological disorders. Led by a team of biopharmaceutical executives, Windward Bio aims to address significant unmet medical needs in this field.
  • Kala Pharmaceuticals — Kala Pharmaceuticals is developing novel treatments for diseases that affect mucosal tissues. The company's proprietary mucus penetrating particle technology dramatically improves drug distribution and pharmacokinetics by uniformly coating the mucosal surface with biocompatible, drug-loaded particles. Kala's formulations achieve high,sustained local drug concentrations with reduced systemic exposure and are delivered in a patient-friendly format. The company's research efforts have demonstrated successful in vivo proof-of-concept in mucosal organs such as the respiratory tract, eye, and cervicovaginal tract, enabling diverse product opportunities that target significant clinical unmet need. Kala is focused on advancing an internal pipeline of products through human proof-of-concept while establishing R&D collaborations with select partners to improve products in their pipelines.
Civilization Ventures VC Fund · San Francisco, California, United States · 5 investments in the past 12 months
DIGITAL HEALTH / AI DIGITAL HEALTH / AI GENE / CELL THERAPIES NASDAQ: RCKT GENE / CELL THERAPIES NASDAQ: RCKT GENOMICS / DIAGNOSTICS GENOMICS / DIAGNOSTICS SYNTHETIC
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Seed, Series A, Series B
  • United States, United Kingdom, Brazil
Portfolio highlights
  • SyntaxBio — SyntaxBio develops CRISPR/Cas9-based, genetic programming platform that converts cells into biological computers using DNA-based instructions that read like lines of code. SyntaxBio's platform can program cells without the need for consistent external intervention.
  • Outpace Bio — Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety.It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacyand safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.
  • Integrated Biosciences — Integrated Biosciences is the first company in history to be able to virtually stress cells.
Prox Ventures VC Fund · Shanghai, Shanghai, China
Proxima Ventures focuses in the healthcare industry, supporting outstanding enterprises with innovative technologies or service models that have tremendous potential.They manage multiple funds in RMB and US dollar, covering from seed to growth stages. Their team members with multidisciplinary backgrounds and resourceful networks, have many yearsof remarkable venture capital experience and achievements. They believe that active and effective collaboration with entrepreneurs will make substantial economic returns while bring meaningful improvements in public health.
Show more
Investment focus
  • Medical, Biotechnology, Health Care
  • Seed, Funding Round, Series A
  • China, United States, United Kingdom
Portfolio highlights
  • Rhino Medical — Rhino Medical develops advanced technologies with independent intellectual property rights. The founding team has rich experience in R&D, marketing, and clinical. On the basis of benchmarking imported phacoemulsification instruments and vitrectomy instruments
  • Cytonus Therapeutics — Cytonus Therapeutics is a biotech company that develops a therapeutic platform designed to treat immune-related disorders. The Cargocyte platform at Cytonus has diverse applications as it can be engineered to target specific tissues and can deliver strategic therapeutic payloads.
  • Rapafusyn Pharmaceuticals — Rapafuysn is pioneering RapaGlues - a modality of non-degrading molecular glues that addresses hard-to-drug targets.
Alix Ventures VC Fund · San Francisco, California, United States
Supporting early stage Life Science startups driving patient impact. Born from our collective experience as founders, we set out to build the fund we wanted to raise from....
Show more
Investment focus
  • Health Care, Biotechnology, Life Science
  • Series A, Seed, Pre-Seed
  • United States
Portfolio highlights
  • Elegen — Skip cloning with NGS-verified, cell-free DNA up to 7 kb. Error rates as low as 1:70,000/bp. Manufactured in USA, shipped globally in 6 to 8 business days. .
  • Zafrens — Zafrens specializes in developing tools and generating insights at the interface of biology, chemistry, and engineering. The company was founded in 2021 and is headquartered in San Diego, California, United States.
  • Galatea Bio — Galatea Bio, a US-based biotechnology company was founder by Carlos Bustamante, Nicholas Katsanis and Alexander Ioannidis. Our mission is to drive groundbreaking discoveries in healthcare by pairing genetic diversity with cutting-edge data analytics. Our passion is fueled by a focus on populations historically underrepresented in genetics research.We achieve this by leveraging our world-class clinical network and biobank, cutting-edge algorithms, and innovative analyses to discover and validate new tests, treatments, and cures that will improve the lives of all.
Jonathan Milner Angel · Cambridge, Massachusetts, United States · 11 investments in the past 12 months
Having worked in the life sciences industry for over ten years as an academic researcher, Jonathan identified the market opportunity for supplying high quality antibodies to support protein interaction studies and, in 1998, founded Abcam with David Cleevely and Professor Tony Kouzarides. Jonathan is a Non-Executive Director of Horizon DiscoveryGroup plc, The Evolution Education Trust, GeoSpock Ltd and Sydicate Room Group Ltd. He is also Chairman of Axol Bioscience Ltd, PhoreMost Ltd, Repositive Limited, Definigen Limited and Cambridge Allergy Ltd. Jonathan holds an executive director position at Meltwind Limited, being a designated member of Meltwind Advisory LLP. Jonathan is an experienced entrepreneur and investor and is passionate about supporting UK life science and high-tech start-ups. He has provided considerable investment and support to over 30 companies and has assisted three AIM IPOs.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Seed, Series A, Series B
  • United Kingdom, United States, Spain
Portfolio highlights
  • Quibim — Leading radiomics company pioneering quantitative imaging biomarkers and medical applications in precision medicine.
  • 52 North Health — At 52 North we are developing fully-integrated clinical, AI and medical-device based systems.
  • Exciting Instruments — Exciting Instruments Limited is a joint company founded in Sheffield that combines the software prowess of Bulldozer Limited with Dr. Timothy Craggs' knowledge of single molecules. Through the use of cloud connectivity and real-time data visualisation, we are a genuine science and software partnership on a mission to assist you in streamliningthe procedure for creating discoveries in biophysics, life sciences, drug discovery, and medical diagnostics.
Hatteras Venture Partners VC Fund · Durham, North Carolina, United States · 2 investments in the past 12 months
Hatteras Venture Partners is a venture capital firm based in Research Triangle Park, NC, with a focus on biopharmaceuticals, medical devices, diagnostics, and related opportunities in human medicine. Founded in 2000, the firm consists of an experienced team with a broad and complementary skill set that is particularly relevant to buildingsuccessful new biomedical companies. The Hatteras Venture Partners team brings operational experience, a successful track record, and a proven ability to enhance the value of the companies in which it invests. With three funds, the firm has more than $120 million under management.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Series A, Series B, Funding Round
  • United States, Canada
Portfolio highlights
  • Endogenex — DyaMX is an early stage medical device company focused on the treatment of Type 2 Diabetes
  • Synaptrix — Synaptrix is committed to offering free of drugs, lasting alternatives for postoperative pain treatment using NOVABLOC.
  • AtaCor Medical — AtaCor Medical Inc., is a San Clemente-based medical device maker. It designs innovative solutions to deliver temporary, interim, and permanent cardiac pacing when, and where it matters most.
Andreessen Horowitz VC Fund · Menlo Park, California, United States · 133 investments in the past 12 months
Andreessen Horowitz (a16z) is a venture capital firm in Silicon Valley, California, investing in bold founders, innovators, and entrepreneurs building the future through technology.
Show more
Investment focus
  • Software, Information Technology, Internet
  • Series A, Seed, Series B
  • United States, United Kingdom, Brazil
Portfolio highlights
  • Hedra — Video creation for everyone.
  • Inductive Bio — Bringing the data, ML, software, and expertise needed to rapidly solve your most challenging ADMET problems.
  • Sprinter Health — Sprinter Health is an on-demand mobile health company that sends full-time nurses and phlebotomists (“Sprinters”) into the home.
Horizons Ventures VC Fund · Hong Kong, Hong Kong Island, Hong Kong · 6 investments in the past 12 months
Investing in the deep science and technology that can propel humanity towards a radically better future.
Show more
Investment focus
  • Biotechnology, Artificial Intelligence, Software
  • Series A, Series B, Seed
  • United States, United Kingdom, Canada
Portfolio highlights
  • Notpla — We are a combination of designers and chemists, engineers and entrepreneurs. We’re hard to define because what we’re doing hasn’t been done before. We create advanced packaging solutions that disappear, naturally.
  • Owlstone Medical — Owlstone Medical has developed a breathalyzer for disease. With a focus on non-invasive diagnostics for cancer, inflammatory disease, and infectious disease, the company aims to save 100,000 lives and $1.5B in healthcare costs.The company’s Breath Biopsy® platform has introduced a new diagnostic modality making it possible to discover novelnon-invasive biomarkers in breath using a platform with the potential to transition to point-of-care. The award-winning ReCIVA Breath Sampler ensures a reliable collection of breath samples. The volatile organic compounds (VOCs) present in the breath are analyzed using proven microchip chemical sensor technology (FAIMS) to detect biomarkers of disease.The Breath Biopsy platform can be used in clinical diagnostics and precision medicine with applications in cancer and a wide range of other medical conditions. Highly sensitive and selective, these tests allow for early diagnosis when treatments are more effective and more lives can be saved.Owlstone Medical is currently developing tests for lung and colorectal cancer, two of the most common cancer killers worldwide, and for asthma stratification by the therapeutic response. The company also Breath Biopsy products and services to academic, clinical, and pharma partners who want to develop breath-based diagnostics for their own applications.
  • Fleet Space Technologies — Fleet is an agile, next generation connectivity company. Our mission is to Connect Everything using cutting-edge communications and space technologies to maximise the resource efficiency of human civilisation and enable the next industrial revolution with our free, ubiquitous connectivity platform.
M Ventures VC Fund · Amsterdam, Noord-Holland, The Netherlands · 18 investments in the past 12 months
Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Seed
  • United States, United Kingdom, Switzerland
Portfolio highlights
  • Biolinq — Introducing a revolutionary platform for metabolic health.
  • ChEmpower — ChEmpower is an advanced materials company that develops chemically reactive, abrasive-free planarization pads to improve chip yields and sustainability in semiconductor manufacturing.
  • Corvic AI — Corvic AI is pioneering a new era of Data-Centric AI Cognitive Infrastructure by transforming raw enterprise data into AI-ready intelligence.
Kurma Partners VC Fund · Paris, Ile-de-France, France · 14 investments in the past 12 months
Kurma Partners is a management company based in Paris, specializing in the financing of innovation in healthcare and biotechnology, from pre-creation to development capital. Kurma Partners, which manages the Kurma Biofund I, II funds and the Kurma Diagnostics fund, is one of the main players in the financing of therapeutic and medical innovationsin Europe, particularly through links with many institutes. research and prestigious hospitals.
Show more
Investment focus
  • Health Care, Biotechnology, Pharmaceutical
  • Series A, Seed, Series B
  • France, Switzerland, Spain
Portfolio highlights
  • DeepUll — DeepUll is a biotech company that focuses its activity on the development of a new diagnostic system for early-stage sepsis condition. DeepUll’s proposal is based on quickly identifying the pathogens and offering the antibiogram within a few hours on the one hand, and on using the data and learning about the patient’s immunological and functionalstatus on the other. The system allows doctors to predict the future appearance and evolution of sepsis within a short period of time and thus provide a suitable clinical response even before the symptoms arise.
  • Nuevocor — Nuevocor is a preclinical-stage biopharmaceutical company focused on developing gene therapy‑based treatments that have the potential to restore cardiac function in diseased hearts.
  • Avidicure — Avidicure is developing dual agonistic avidity-engineered multifunctional antibodies, AVC-Boosters, as monotherapy for treatment of cancer
MPM Capital VC Fund · Cambridge, Massachusetts, United States
Powering Breakthroughs in Life Sciences
Show more
Investment focus
  • Biotechnology, Health Care, Pharmaceutical
  • Series B, Series A, Series C
  • United States, United Kingdom, Canada
Portfolio highlights
  • Firefly Bio — Firefly specializes in Degrader Antibody Conjugates (DACs) which combine the unique strengths of ADCs with selective protein degraders.
  • Umoja Biopharma — Pioneering immunotherapy by reprogramming T cells in vivo to target cancer cells.
  • Frontier Medicines — Frontier Medicines is boldly advancing science to defeat disease by pioneering innovations in precision-based medicines to target undruggable therapies
Lux Capital VC Fund · New York, New York, United States · 34 investments in the past 12 months
Lux Capital manages over $5 billion in assets focused on founding, seed, early-stage, and growth investments at the intersection of technology and the sciences. Lux takes an active role in helping entrepreneurs build successful businesses in high-growth sectors. Its investment team has built over 20 companies from scratch. Lux's investmentstrategy ensures portfolio companies are better connected, have a deeper insight, and command industry leadership faster than their competitors.
Show more
Investment focus
  • Software, Health Care, Biotechnology
  • Series A, Seed, Series B
  • United States, United Kingdom, Canada
Portfolio highlights
  • Saildrone — Saildrone is the world leader in oceangoing autonomous surface vehicles, providing unrivaled payload, range, and reliability from an uncrewed system.
  • Inductive Bio — Bringing the data, ML, software, and expertise needed to rapidly solve your most challenging ADMET problems.
  • Jericho Security — Train your team to defend against the latest cyber attacks with our complete cybersecurity platform.
KdT Ventures VC Fund · Austin, Texas, United States · 5 investments in the past 12 months
KdT Ventures is the standard for early-stage frontier science investing.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Seed, Series A, Series B
  • United States, Israel, Germany
Portfolio highlights
  • Shiprocket — Shiprocket is India's most-used eCommerce logistics and shipping software solution for the best courier services. Avail features like COD (Cash on Delivery), prepaid delivery, automated shipping, etc.
  • March Biosciences — Transforming Patient Care by Unlocking New Target Spaces March Biosciences is a clinical-stage company in the cell therapy field focused on developing CAR-T cell strategies to address the most challenging hematological cancers Pipeline MB-105 https://march.bio/wp-content/uploads/2023/05/shutterstock_1008023995-HD-30.mp4 Focused on Excellence Target Space Our approach combines biological and engineering insights to enable target-unlock without the risk and complexity
  • Montara Therapeutics — Montara Therapeutics is a precision-medicine neuroscience biotech startup improving safety and efficacy of therapies for people with neurological diseases
Roche Venture Fund VC Fund · Basel, Basel-Stadt, Switzerland
The Roche Venture Fund is the name given to the corporate venture fund of the healthcare company Roche. Roche has allocated CHF 500 million to invest in and develop commercially successful innovative life science companies. Roche has been investing in early stage companies as part of collaborations since the early-1990s and independent ofcollaborations since 2002. All equity investments made by Roche in biotech and diagnostics companies (including collaboration investments) are negotiated and managed by the Roche Venture Fund. In the past 20 years, the Roche Venture Fund has invested in over 60 companies globally. Currently, Roche Venture Fund has a portfolio of around 30 companies located in 10 countries across Europe, North America and the Pacific Region. The fund is an evergreen fund with CHF 500 million available of which approximately 40% is currently invested.The Roche Venture Fund is a committed long-term stable investor with sufficient money reserved in their fund for follow-on financing rounds. As part of a multinational healthcare company, the Roche Venture Fund has access to considerable expertise both internally and externally. We co-invest with leading venture funds, including other corporate venture funds, on a regular basis.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series B, Series A, Series C
  • United States, United Kingdom, Spain
Portfolio highlights
  • DiogenX — Welcome to DiogenX. Explore our pioneering research and innovative therapies aimed at transforming diabetes treatment
  • Mironid — Google Analytics is a web analysis service provided by Google. Google utilizes the data collected to track and examine the use of www.mironid.com, to prepare reports on its activities and share them with other Google services. Google may use the data collected to contextualize and personalize the ads of its own advertising network.
  • MISSION Therapeutics — Deubiquitylating enzymes: multiple drug opportunities across therapeutic areas
Takeda Ventures VC Fund · San Diego, California, United States · 3 investments in the past 12 months
Takeda Ventures, Inc. (TVI) is the corporate investment arm of Takeda Pharmaceutical Company Limited (TPC). TVI was founded in 2001 and invests in current and future areas of interest for TPC. They are based alongside Takeda’s R&D sites in Cambridge, MA, and San Diego, CA. As a strategic investor, TVI aims to provide support and guidance toentrepreneurs and early-stage companies driving concepts through clinical proof of concept. They also strive to forge active, collaborative interactions that result in synergies with Takeda's considerable R&D resources. Their goal is to build a portfolio of strategic investments, with an immediate emphasis on oncology, gastroenterology, neuroscience, and rare diseases.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Funding Round
  • United States, United Kingdom, Israel
Portfolio highlights
  • Be Biopharma — Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.
  • Degron Therapeutics — Degron Therapeutics is a leading platform company in discovery of molecular glue degraders for cancer treatment.
  • EvolveImmune Therapeutics — EvolveImmune Therapeutics transforms the discovery and development of novel immunotherapies. By leveraging its proprietary in vivo target discovery platform, EvolveImmune is building a pipeline of novel therapeutic candidates against numerous targets that are expressed on multiple immune cell types. The company’s platform will generatefirst-in-class treatments for unmet needs in oncology and autoimmune diseases.
Casdin Capital VC Fund · New York, New York, United States · 7 investments in the past 12 months
Casdin Capital is a fundamental research investment firm focused on the life sciences and healthcare industry. It manages a long-short equity fund and makes investments in early-stage to late-stage private investments. Casdin was launched in 2012 by founder and CIO Eli Casdin and as of October 2020 has approximately $2.2 billion in assets undermanagement.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series B, Series A, Series C
  • United States, France, China
Portfolio highlights
  • Leyden Labs — Leyden Labs helps people live freely by developing products that protect from known and new respiratory viruses.
  • nChroma Bio — nChroma Bio's integrated product engine allows for safe, accurate, and targeted in vivo administration, addressing major shortcomings of current genetic medicine techniques.
  • Auron Therapeutics — A differentiated approach to cure cancer.
Novo Holdings VC Fund · Hellerup, Hovedstaden, Denmark · 27 investments in the past 12 months
Novo Holdings is a world-leading life science investor with a focus on creating long-term value.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Series A, Series B, Series C
  • United States, Denmark, United Kingdom
Portfolio highlights
  • Supira Medical — Next Generation Solution for Temporary Mechanical Circulatory Support Developing a low-profile, high-flow percutaneous ventricular assist device (pVAD) for high risk coronary intervention and cardiogenic shock. Clinical Need Percutaneous ventricular assist devices (pVADs) are placed to provide temporary mechanical support, assisting the native pumping action of
  • Sparrow Quantum — Sparrow Quantum, a global leader in quantum photonic chip technology. Explore innovative solutions driving advancements in quantum computing, communication, and beyond. Stay ahead with cutting-edge technologies shaping the future.
  • Tribune Therapeutics — Tribune Therapeutics is a preclinical biopharmaceutical company building a promising pipeline of novel medicines to treat patients with a wide range of fibrotic diseases.
Sahsen Ventures VC Fund · Seattle, Washington, United States · 2 investments in the past 12 months
Sahsen Ventures is a venture capital firm making investments in for-profit and nonprofit organizations with an emphasis on technology and biotechnology. It was established in 2016 and is based in Seattle, Washington.
Show more
Investment focus
  • Biotechnology, Health Care, Non Profit
  • Funding Round, Series A, Seed
  • United States, China, Ghana
Portfolio highlights
  • Insamo — Insamo is a global biotechnology company pioneering the discovery of membrane-permeable and orally available cyclic-peptides with antibody-like binding affinity.
  • Outpace Bio — Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety.It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacyand safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.
  • Archon Biosciences — Archon is a biotechnology firm that creates computationally engineered proteins to unleash potent therapeutic targets beyond the grasp of current methods and improve disease management.
Omega Funds VC Fund · Boston, Massachusetts, United States · 12 investments in the past 12 months
We aim to invest in exceptional founders and entrepreneurs and impactful products and platforms across multiple therapeutic areas.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Series C
  • United States, Switzerland, United Kingdom
Portfolio highlights
  • Windward Bio — Windward Bio is a clinical-stage drug development company focused on improving outcomes for individuals with advanced immunological diseases, particularly severe respiratory conditions. The company is advancing a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 development while creating innovative bispecific programsfor various immunological disorders. Led by a team of biopharmaceutical executives, Windward Bio aims to address significant unmet medical needs in this field.
  • Alleviant Medical — Interventional therapy for congestive heart failure
  • Callio Therapeutics — Callio Therapeutics focuses on developing next-generation, multi-payload antibody-drug conjugates to maximize therapeutic benefits.
Dementia Discovery Fund VC Fund · London, England, United Kingdom · 5 investments in the past 12 months
SV Health Investors is a specialist healthcare fund manager, investing across multiple stages and sectors. Our goal is to transform healthcare one investment at a time.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Seed, Funding Round
  • United States, United Kingdom, Israel
Portfolio highlights
  • Therini Bio — Therini Bio is developing novel therapeutics based insights into the role of fibrin in driving chronic innate immune activation.
  • Montara Therapeutics — Montara Therapeutics is a precision-medicine neuroscience biotech startup improving safety and efficacy of therapies for people with neurological diseases
  • TRIMTECH Therapeutics — Transformative treatments for CNS and inflammatory disorders by selectively destroying disease-causing protein aggregates
JDRF T1D Fund VC Fund · Boston, Massachusetts, United States
The JDRF T1D Fund (www.t1dfund.org) is a venture philanthropy fund exclusively devoted to finding and funding the best early-stage T1D commercial opportunities to accelerate the delivery of treatments, preventions, and cures to patients. It was created to solve a critical funding gap in the T1D drug and device development pipeline. Throughpartnerships with private capital, including venture capital, pharma and foundations, the T1D Fund anticipates that it will be able to attract substantially more private investment to the T1D field than occurs today. The T1D Fund will initially focus on artificial pancreas systems, metabolic control, beta cell replacement, prevention, and beta cell restoration therapies, with an exclusive priority on the best commercial opportunities. The T1D Fund will reinvest any realized gains into new investments to further its mission.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Funding Round, Series B
  • United States, France, Italy
Portfolio highlights
  • vTv Therapeutics — vTv Therapeutics, a pharmaceutical company, focuses on the discovery and development of human therapeutics to fill unmet medical needs. Its mission is to utilize its innovative technology to rapidly translate the functional modulation of human proteins into safe and effective medicines.vTv Therapeutics has a pipeline of small molecule clinicaland pre-clinical drug candidates for the treatment of a wide range of human diseases including central nervous system disorders, metabolic disorders, inflammation, and cancer. The company has built its product candidate portfolio through internal discovery and is advancing its product candidates through in-house research and development efforts. The quality and breadth of vTv's product candidate pipeline, platform technology, scientific team, and strategic collaborations have enabled it to become a fully integrated pharmaceutical company.The company's commitment to drug discovery is reflected in its medical solutions and the many exciting potential new treatment options in its pipeline. The company's major R&D activities have focused on central nervous system disorders, metabolic disorders, inflammation and oncology.vTv Therapeutics is advancing several proprietary drug candidates. The company's lead candidate, azeliragon (aka TTP488), is a novel, orally bioavailable small molecule compound that is being developed for the treatment of Alzheimer's disease. In Phase 2 clinical trial in patients with mild to moderate Alzheimer's disease, azeliragon showed a statistically significant difference of more than 3 points in ADAS-cog at 18 months compared to placebo.Azeliragon has been granted Fast Track Designation and agreement on its Phase 3 protocol has been reached with FDA via a Special Protocol Assessment (SPA). The Phase 3 study in patients with mild Alzheimer's disease was initiated in April 2015 with a clear path forward to registration with the aim to demonstrate disease modification.vTv Therapeutics is also prosecuting the clinical development of TTP399, a novel functionally liver-selective Glucokinase Activator ("GKA") for the treatment of type 2 diabetes. In a Phase 2a study, TTP399 normalized patients' HbA1c without inducing hypoglycemia, after only six weeks of treatment. A six-month Phase 2 study is ongoing.
  • Eledon Pharmaceuticals — Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people undergoing organ or cellular transplantation, and for people with autoimmune and neurodegenerative disease.
  • Cour Pharmaceuticals Development — COUR Pharmaceuticals is developing first-in-class therapies designed to reprogram the immune system to achieve antigen-specific tolerance...
5AM Ventures VC Fund · Menlo Park, California, United States · 6 investments in the past 12 months
5AM Ventures is a venture capital firm that offers seed- and early-stage investments to its clients. The company’s client portfolio consists of firms in the biopharmaceutical, life sciences, medical technology, and research instrument industries. 5AM Ventures was founded in 2002 by John Diekman and Andrew Schwab and is based in California.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Series C
  • United States, Switzerland, United Kingdom
Portfolio highlights
  • Surrozen — Surrozen is a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway. Surrozen is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with potential application across multiple disease areas, including diseases of the intestine, liver, retina,cornea, lung, kidney, cochlea, skin, pancreas and central nervous system.
  • nChroma Bio — nChroma Bio's integrated product engine allows for safe, accurate, and targeted in vivo administration, addressing major shortcomings of current genetic medicine techniques.
  • Latigo Biotherapeutics — Operator of a drug discovery company intended to develop novel, non-opioid therapies for chronic pain. The company utilizes unique, translated insights to provide a differentiated approach to targeting therapeutics across the blood-nerve barrier, enabling patients to get access to a pain management therapy that does not create addiction, dependenceor tolerability.
Seventure Partners VC Fund · Paris, Ile-de-France, France · 14 investments in the past 12 months
Seventure Partners is a French venture capital firm targeting in Tech/Digital and Life Sciences companies. It funds innovation and participates in the entrepreneurial adventure, alongside entrepreneurs and sharing their passion.Founded in 1997, Seventure Partners is one of the European leaders in venture capital, with € 1 billion undermanagement as of December 31, 2023. It is an active partner of innovative companies that, according to the management team, show strong growth potential and evolving in two fields of activity: Digital Technologies and Life Sciences. With more than 20 employees, including some 15 investors, Seventure Partners has a proven track record and in-depth expertise in technology, entrepreneurship, and various private equity operations.Seventure's goal is to identify and support the development of tomorrow's European leaders in order to accelerate their growth. To do this, the firm provides entrepreneurs with the expertise, networks, and know-how of its internal team of investors.The different funds/verticals on which Seventure Partners are focusing on today: - Life Sciences : Biotech, Healthcare, Nutrition - Tech/Digital : B2B SaaS, Fintech, Retailtech, Cybersecurity - Sports & Wellbeing - Blue Economy
Show more
Investment focus
  • Biotechnology, Health Care, Software
  • Series A, Funding Round, Series B
  • France, United States, Germany
Portfolio highlights
  • Ekstere — Ekstere facilitates selling and purchasing verified-quality used bicycles at a reasonable price.
  • Anybuddy — Anybuddy is a sport booking marketplace, leader in racket sport in France
  • Seaweed Concept — Seaweed Concept is a marine biotechnology company, that focuses on the innovative utilization of seaweed to provide high-quality ingredients to various industrial sectors
Khosla Ventures VC Fund · Menlo Park, California, United States · 67 investments in the past 12 months
Khosla Ventures is a venture capital firm that invests in early- to late-stage companies across sectors like AI, healthcare, sustainability, and consumer technology. It manages multiple funds, focusing on startups with innovative technologies or business models. The firm primarily targets sectors like AI, climate tech, digital health, and medtech,offering strategic support to help build long-lasting companies.
Show more
Investment focus
  • Software, Health Care, Artificial Intelligence
  • Series A, Series B, Seed
  • United States, India, United Kingdom
Portfolio highlights
  • Somite — Somite.ai is on a mission to transform the lives of millions of people by leveraging AI to produce human tissue for cell-based therapies.
  • Realta Fusion — Realta Fusion develops fusion energy technology for the production of industrial heat and power. It applies advances in super-conducting materials, plasma physics, and computing power to a simple linear fusion reactor configuration. It utilizes abundant fuel sources to provide a zero-carbon source of heat and power.
  • Cartwheel — Cartwheel is a powerful new way to animate characters for videos, games, 3D, movies, ads or social media.
Artis Ventures VC Fund · San Francisco, California, United States · 4 investments in the past 12 months
Artis Ventures has spent over a decade backing bold teams who take the hard path, building market-defining companies to re-shape, re-invent, and re-make industries.
Show more
Investment focus
  • Health Care, Biotechnology, Software
  • Series A, Series B, Seed
  • United States, India, Germany
Portfolio highlights
  • Network Bio — Network Bio is a clinical and molecular data library enabling precision medicine approaches for common human diseases. Its platform delivers a centralized repository for clinical and molecular data that allows researchers to identify patterns and correlations that can be used to develop new treatments and diagnostic tools.
  • Outpace Bio — Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety.It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacyand safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.
  • Second Front Systems — The continuous accreditation and deployment of commercial software is crucial for U.S. national security missions. With Second Front Systems' Game Warden platform, you'll be achieving exactly that.
Rev1 Ventures VC Fund · Columbus, Ohio, United States · 5 investments in the past 12 months
Rev1 Ventures provides seed stage venture capital funding in Columbus, Ohio along with startup services, space, mentoring, and connections. Learn more!
Show more
Investment focus
  • Software, Health Care, Information Technology
  • Seed, Series A, Funding Round
  • United States, Germany
Portfolio highlights
  • Myoptechs — Myoptechs, a pediatric ophthalmic medical device startup in the clinical stage, has made advancements in its fund-raising and clinical research program. The company creates innovative soft contact lenses and spectacles that reduce the growth of myopia while offering incredibly clear vision.
  • Nichefire — Nichefire is an AI-power marketing analytics company.
  • STAQ Pharma — STAQ Pharma is an FDA-registered 503B outsourcing partner that provides critical medications for pediatric and adult patients across the country. As a hospital-backed and directed pharmaceutical outsourcing partner, STAQ Pharma is positioned to strengthen the supply chain for drug shortages, understand provider needs, and ensure safety in critical medications.
Cormorant Asset Management VC Fund · Boston, Massachusetts, United States · 16 investments in the past 12 months
Cormorant Asset Management is an employee-owned hedge fund sponsor that provides its services to pooled investment vehicles. The firm also focuses on both public and private market innovative companies in the biotechnology and life sciences marketplace.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Series B, Series A, Series C
  • United States, China, Switzerland
Portfolio highlights
  • Numab — Numab Therapeutics AG
  • Neurona Therapeutics — Neurona Therapeutics is a pre-clinical stage biotechnology company that was founded by four neuroscientists and stem cell pioneers at The University of California, San Francisco. They are focused on the discovery and development of cell-based therapies to treat intractable neurological disease. Its initial aim is to generate therapeuticcompositions of a specific type of nerve cell (or neuron) for targeted delivery into the injured nervous system. Based on nearly two decades of research, they believe that particular subpopulations of neurons have the unique ability to integrate and repair dysregulated neural circuits. Its talented team of scientists, scientific advisors, and board directors is working to accelerate breakthrough treatments for patients with significant unmet medical needs.
  • Edgewise Therapeutics — See how we bring our unique expertise and singular focus on muscle science to develop novel therapeutics for serious skeletal and cardiac muscle diseases.
F-Prime Capital VC Fund · Cambridge, Massachusetts, United States · 32 investments in the past 12 months
F-Prime Capital is a global venture capital firm investing in healthcare and technology, with a heritage that spans four decades.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Series A, Series B, Series C
  • United States, United Kingdom, China
Portfolio highlights
  • Dinari — Discover Equity Boundless - Simplify everything from equity management and options grant to payroll so that you no longer have to worry about compliance, taxes, or vesting schedules no matter where your employees are.
  • Toku — Toku helps companies to automate collections and facilitate payment processes. Toku enables companies to optimize the collection of recurring payments.
  • Galatea Bio — Galatea Bio, a US-based biotechnology company was founder by Carlos Bustamante, Nicholas Katsanis and Alexander Ioannidis. Our mission is to drive groundbreaking discoveries in healthcare by pairing genetic diversity with cutting-edge data analytics. Our passion is fueled by a focus on populations historically underrepresented in genetics research.We achieve this by leveraging our world-class clinical network and biobank, cutting-edge algorithms, and innovative analyses to discover and validate new tests, treatments, and cures that will improve the lives of all.
High-Tech Gruenderfonds VC Fund · Bonn, Nordrhein-Westfalen, Germany · 47 investments in the past 12 months
The seed investor High-Tech Gründerfonds (HTGF) finances tech start-ups with growth potential and has supported more than 700 start-ups since 2005. With the launch of its fourth fund, HTGF now has about 1.4 billion euros under management. Its team of experienced investment managers and start-up experts support young companies with expertise,entrepreneurial spirit and passion. HTGF’s focus is on high-tech start-ups in the fields of digital tech, industrial tech, life sciences, chemistry and related business areas. To date, external investors have injected about 5 billion euros of capital into the HTGF portfolio via more than 2,000 follow-on financing rounds. In addition, HTGF has already successfully sold shares in more than 170 companies. Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries. Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries.
Show more
Investment focus
  • Software, Biotechnology, Information Technology
  • Seed, Series A, Funding Round
  • Germany, Switzerland, United States
Portfolio highlights
  • AICA SA — AICA believes programming robots should be at everyone's reach. We combine Artificial Intelligence & an intuitive interface, to help you relocate your production.
  • ctrl+s — High resolution insights into the deep supply chain are the building blocks for every substantive sustainability strategy and effective decarbonization.
  • Akribion Genomics — Specific, versatile, effective RNA-guided cell depletion
Oxford Science Enterprises VC Fund · Oxford, Oxfordshire, United Kingdom · 9 investments in the past 12 months
Oxford Science Enterprises is the university-partnered venture firm. We work with the University of Oxford to build companies that create fundamental technologies: science-based businesses capable of tackling the planet’s toughest problems. We invest in life science, AI and software, healthcare, and deep tech to create companies taking onchallenges like nuclear fusion, quantum computing and developing treatments and cures for infectious diseases. Founded in 2015, we’ve raised over £600M to create a world-class technology ecosystem, and combine our deep experience with a network of investors, entrepreneurs and sector-experts to find co-investment, build businesses, and hire senior management talent.
Show more
Investment focus
  • Health Care, Biotechnology, Software
  • Series A, Seed, Series B
  • United Kingdom, United States, The Netherlands
Portfolio highlights
  • FluoRok — By employing our patented technology, we can produce fluorochemicals without the production of toxic and highly dangerous hydrofluoric acid
  • Neu Health — Neu Health enables clinicians, care givers and patients to tackle this growing challenge with cutting-edge digital technologies designed to make the latest care accessible for all, improving outcomes today and accelerating future breakthroughs.
  • Salience Labs — Salience Labs is building a hybrid photonic-electronic chip for AI. We have designed a massively parallel, ultra-high-throughput Photonic Tensor Processing Unit. Photonics allows data to be modulated at up to 100 GHZ, and allows for high levels of parallelization using multiplexing. We integrate this photonic unit into a SoC architecture designedto exploit its high throughput for AI inference. Salience Labs technology is based on decades of research collaboration between Oxford University and the University of Münster, Germany.
New Enterprise Associates VC Fund · Menlo Park, California, United States · 54 investments in the past 12 months
Foundational partners to ambitious founders at every stage of company-building.
Show more
Investment focus
  • Software, Health Care, Biotechnology
  • Series B, Series A, Series C
  • United States, India, Canada
Portfolio highlights
  • Ceramic.ai — Ceramic.ai builds enterprise-grade infrastructure to optimize how companies train and deploy their AI models
  • Vori Health — Meet Vori Health, the new virtual and in-person musculoskeletal healthcare company that will help you get that spring back into your step.
  • Ceramic — Next generation AI training systems for better models with less compute, less time, and lower costs.
Investors by industry
Investors by country
Investors in Life Science by country
Angel investors in Life Science by country
VC (Venture Capital) Funds in Life Science by country